Genetic study of a family with affected members with Waardenburg syndrome type 4 without Hirschsprung disease
DOI:
https://doi.org/10.15584/ejcem.2020.2.3Keywords:
EDN3 gene, Waardenburg syndrome, WS4Abstract
Introduction. Waardenburg syndrome (WS) is an autosomally inherited disorder with the most common state compounding pigmentary abnormality and sensorineural deafness. The rarest type of the disease is WS4 with the general characteristic discriminated from other types by the attendance of Hirschsprung disease (HD). Among the several genes, one of the causative genes in WS4 is endothelin 3 (EDN3) with both autosomal recessive and dominant inheritance.
Aim. The intention of the present study is to report a pathogenic mutation as the genetic cause of WS in an Iranian family with four patients without any segregation criteria for the type of the disease.
Material and methods. In order to detect of causing gene or genes related to the disease, Whole exome sequencing (WES) technique in proband’s sample was done. To confirm the detected mutation in proband and some family members with or without the disease direct sequencing of END3 gene was performed using Sanger method.
Results. Pedigree analysis suggested segregation of WS as an autosomal recessive trait in the family. WES analysis suggested a gene (EDN3) related to WS type 4B. DNA sequencing confirmed a pathogenic missense mutation c.293C>T, p.T98M in EDN3 gene in all of the four patients.
Conclusion. Determination of WS can usually be missed owing to the lack of some attributes in every sufferer and also conventional clinical variance, in spite of several affected members in a single family. So, Genetic counseling is pivotal for families with multiple members influenced. We detected c.293C>T, p.T98K mutation in EDN3 gene as a pathogenic variant which has been known as a likely pathogenic state in the American College of Medical Genetics and Genomics (ACMG) guidelines, despite one prior report. It will be helpful in genetic diagnosis of affected persons and increases the mutation spectrum of EDN3 gene.
Downloads
References
Liu Q, Cheng J, Lu Y, et al. The clinical and genetic research of Waardenburg syndrome type I and II in Chinese families. Int J Pediatr Otorhinolaryngol. 2020;130:109806.
Li W, Mei L, Chen H, et al. New Genotypes and Phenotypes in Patients with 3 Subtypes of Waardenburg Syndrome Identified by Diagnostic Next-Generation Sequencing. Neural Plast. 2019;2019:7143458.
Barashkov NA, Romanov GP, Borisova UP, et al. A rare case of Waardenburg syndrome with unilateral hearing loss caused by nonsense variant c. 772C> T (p. Arg259*) in the MITF gene in Yakut patient from the Eastern Siberia (Sakha Republic, Russia). Int J Circumpolar Health. 2019;78(1):1630219.
Nusrat M, Tariq MA, Aslam S, Zil-E-Ali A, Shahid M, Mahmood S. A Case of Waardenburg-Shah Syndrome Type 4 Presenting with Bilateral Homochromatic Blue Irises from Pakistan. Cureus. 2018;10(8):e3143.
Sadiq S, Langah A, Siyal AA, Ali NU. Waardenburg Syndrome: A Case Report. AJPR. 2019;2:1-4.
Liang F, Zhao M, Fan L, Zhang H, Shi Y, Han R, Qu C. Identification of a de novo mutation of SOX10 in a Chinese patient with Waardenburg syndrome type IV. Int J Pediatr Otorhinolaryngol. 2016;91:67-71.
Newton VE. Clinical features of the Waardenburg syndromes. Adv Otorhinolaryngol. 2002;61:201-208.
Pang X, Zheng X, Kong X, et al. A homozygous MITF mutation leads to familial Waardenburg syndrome type 4. Am J Med Genet A. 2019;179(2):243-248.
Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature. 2007;445(7130):843-850.
Shamseldin HE, Rahbeeni Z, Alkuraya FS. Perturbation of the consensus activation site of endothelin‐3 leads to Waardenburg syndrome type IV. Am J Med Genet A. 2010;152(7):1841-1843.
Hofstra RM, Osinga J, Tan-Sindhunata G, et al. A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome). Nature genetics. 1996;12(4):445-447.
Kapoor S, Bindu PS, Taly AB, et al. Genetic analysis of an Indian family with members affected with Waardenburg syndrome and Duchenne muscular dystrophy. Mol Vis. 2012;18:2022.
Shin MK, Levorse JM, Ingram RS, Tilghman SM. The temporal requirement for endothelin receptor-B signalling during neural crest development. Nature. 1999;402(6761):496-501.
Lee HO, Levorse JM, Shin MK. The endothelin receptor-B is required for the migration of neural crest-derived melanocyte and enteric neuron precursors. Dev Biol. 2003;259(1):162-75.
Baynash AG, Hosoda K, Giaid A, et al. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell. 1994;79(7):1277-1285.
Svensson PJ, Von Tell D, Molander ML, Anvret M, Nordenskjöld A. A heterozygous frameshift mutation in the endothelin-3 (EDN-3) gene in isolated Hirschsprung's disease. Pediatric research. 1999;45(5):714-717.
Sznajer Y, Coldéa C, Meire F, Delpierre I, Sekhara T, Touraine RL. A de novo SOX10 mutation causing severe type 4 Waardenburg syndrome without Hirschsprung disease. Am J Med Genet A. 2008;146A(8):1038-1041.
Bolk S, Pelet A, Hofstra RM, et al. A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus. PNAS. 2000;97(1):268-273.
Inoue K, Khajavi M, Ohyama T, et al. Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nature genetics. 2004;36(4):361-369.
Touraine RL, Attié-Bitach T, Manceau E, et al. Neurological phenotype in Waardenburg syndrome type 4 correlates with novel SOX10 truncating mutations and expression in developing brain. Am J Hum Genet. 2000;66(5):1496-1503.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
